Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-16 pm EDT			After market 07:43:46 pm
69.17 ^USD	+1.30%		69.80	+0.91%

Sep. 16	North American Morning Briefing : Investors Primed -2-	DJ
Sep. 13	Health Care Up on Cyclical Bias -- Health Care Roundup	DJ

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

North American Morning Briefing : Investors Primed -2-	Sep. 16	DJ
Health Care Up on Cyclical Bias -- Health Care Roundup	Sep. 13	DJ
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says	Sep. 13	MT
A central bank and it's off again?	Sep. 13
Analyst recommendations: Oracle, McDonald's, S&P Global, Adobe...	Sep. 13
Leerink Partners Adjusts Moderna Price Target to $46 From $58	Sep. 13	MT
Goldman Sachs Cuts Moderna's Price Target to $139 From $178	Sep. 13	MT
MODERNA : JP Morgan lowers to Sell rating	Sep. 13	ZD
Moderna Shares Fall Pre-Bell, Price Targets Downgraded After R&D Spending Cuts	Sep. 13	MT
TD Cowen Adjusts Price Target on Moderna to $60 From $70	Sep. 13	MT
Barclays Adjusts Price Target on Moderna to $125 From $155	Sep. 13	MT
JPMorgan Downgrades Moderna to Underweight From Neutral, Cuts Price Target to $70 From $88	Sep. 13	MT
Oppenheimer Downgrades Moderna to Market Perform From Outperform	Sep. 13	MT
Oddo BHF Adjusts Price Target on Moderna to $96 From $125	Sep. 13	MT
Piper Sandler Lowers Price Target on Moderna to $115 From $157	Sep. 13	MT
Brookline Capital Cuts Price Target on Moderna to $238 From $310	Sep. 13	MT
North American Morning Briefing: Stock Futures Edge Up as Investors Assume Fed Cut on Cards	Sep. 13	DJ
Futures muted on uncertainty about Fed rate-cut size	Sep. 13	RE
Jefferies Downgrades Moderna to Hold, Price Target is $65	Sep. 13	MT
RBC Cuts Price Target on Moderna to $75 From $90, Keeps Sector Perform Rating	Sep. 13	MT
MODERNA : Oddo BHF reduces its target after CMD	Sep. 13	CF
Wall St. rises as PPI data keeps smaller rate cut in view	Sep. 12	RE
Equity Markets Rise as Traders Weigh Macro Data	Sep. 12	MT
Equity Markets Rise as Traders Weigh Macro Data	Sep. 12	MT
US Equities Markets End Higher Thursday as Traders Parse Macro Data	Sep. 12	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2024-10-30 - Q3 2024 Earnings Release (Projected)

More about the company